Who was studied?
66 enrolled patients as of 31 October 2024.
What does the publication report?
ORR was 22.7%, DCR 56.1%, median PFS 4.3 months and median OS 10.3 months.
Safety findings
57 patients had treatment-related events; six had grade 3 or higher events.
How should we interpret it?
Conference abstract with limited methodological detail and no randomized comparator; linked to the same PRaG 2.0 study, not a separate trial.
Read the original source
This independently written summary was checked against the publicly available abstract. It is not a translation of the full paper or a clinical recommendation.
PD-1 inhibitors combined with radiotherapy and GM-CSF, sequentially followed by IL-2 regimen in advanced refractory solid tumors: a prospective, multicenter clinical trial. · DOI: 10.1200/JCO.2025.43.16_suppl.2616
Other publications from this study
Educational reporting, not individualized medical advice. Discuss treatment decisions with your clinical team.